fluoxetine has been researched along with Tuberculosis, Multidrug-Resistant in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb." | 1.72 | An effective nano drug delivery and combination therapy for the treatment of Tuberculosis. ( Amiri, V; Delorme, V; Ebrahimzadeh, N; Kasaeian, A; Maleki, M; Masoumi, M; Pourazar, S; Sadeghinia, M; Sheikhpour, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sheikhpour, M | 1 |
| Delorme, V | 1 |
| Kasaeian, A | 1 |
| Amiri, V | 1 |
| Masoumi, M | 1 |
| Sadeghinia, M | 1 |
| Ebrahimzadeh, N | 1 |
| Maleki, M | 1 |
| Pourazar, S | 1 |
1 other study available for fluoxetine and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Fluoxetine; Humans; Isoniazid | 2022 |